doi: 10.1016/s0960-894x(98)00610-6.
Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin
Affiliations
- PMID: 9873732
- DOI: 10.1016/s0960-894x(98)00610-6
Item in Clipboard
Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin
Bioorg Med Chem Lett.
.
Abstract
Substrates containing doxorubicin (DOX), paclitaxel (taxol), and mitomycin C (MMC) attached to the cathepsin B-sensitive dipeptide Phe-Lys via a self-immolative spacer were prepared as model compounds for internalizing anticancer immunoconjugates. Cathepsin B-mediated release rates of free drug, rat liver lysosomal susceptibility and human plasma stability were measured for each.
Similar articles
-
Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin.Bioorg Med Chem Lett. 1998 Dec 1;8(23):3341-6. doi: 10.1016/s0960-894x(98)00609-x. Bioorg Med Chem Lett. 1998. PMID: 9873731
-
Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity.Bioconjug Chem. 2002 Jul-Aug;13(4):855-69. doi: 10.1021/bc025536j. Bioconjug Chem. 2002. PMID: 12121142
-
Development of protein-binding bifunctional linkers for a new generation of dual-acting prodrugs.Bioconjug Chem. 2009 Feb;20(2):390-6. doi: 10.1021/bc800429q. Bioconjug Chem. 2009. PMID: 19199576
-
Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review).Int J Oncol. 2013 Feb;42(2):373-83. doi: 10.3892/ijo.2012.1754. Epub 2012 Dec 28. Int J Oncol. 2013. PMID: 23291656 Free PMC article. Review.
-
[Glucuronyl paclitaxel (Taxol) derivatives as tumor activated prodrugs].Ann Pharm Fr. 2005 Jan;63(1):53-62. doi: 10.1016/s0003-4509(05)82251-5. Ann Pharm Fr. 2005. PMID: 15803101 Review. French.
Cited by
-
Modular Development of Enzyme-Activatable Proteolysis Targeting Chimeras for Selective Protein Degradation and Cancer Targeting.JACS Au. 2024 May 16;4(7):2564-2577. doi: 10.1021/jacsau.4c00298. eCollection 2024 Jul 22. JACS Au. 2024. PMID: 39055140 Free PMC article.
-
Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer.Oncotarget. 2017 Dec 14;9(2):1957-1968. doi: 10.18632/oncotarget.23319. eCollection 2018 Jan 5. Oncotarget. 2017. PMID: 29416744 Free PMC article.
-
Controlling rates and reversibilities of elimination reactions of hydroxybenzylammoniums by tuning dearomatization energies.Chem Sci. 2024 Jun 7;15(27):10448-10454. doi: 10.1039/d4sc02985b. eCollection 2024 Jul 10. Chem Sci. 2024. PMID: 38994402 Free PMC article.
-
Synthesis and Preclinical Evaluation of a Highly Improved Anticancer Prodrug Activated by Histone Deacetylases and Cathepsin L.Theranostics. 2016 Mar 28;6(6):808-16. doi: 10.7150/thno.13826. eCollection 2016. Theranostics. 2016. PMID: 27162551 Free PMC article.
-
A cell-penetrating peptidic GRP78 ligand for tumor cell-specific prodrug therapy.Bioorg Med Chem Lett. 2008 Mar 1;18(5):1632-6. doi: 10.1016/j.bmcl.2008.01.060. Epub 2008 Jan 19. Bioorg Med Chem Lett. 2008. PMID: 18243696 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
